Pfizer loses bid to reup Lipitor patent
- Share via
From Times Wire Services
Pfizer Inc. has lost a preliminary bid to gain reissuance of one of the U.S. patents protecting its Lipitor cholesterol medicine.
Should the ruling stand, Pfizer would face U.S. generic competition to Lipitor, the world’s top-selling drug, in March 2010 rather than in June 2011.
Pfizer’s sales for Lipitor were $12.9 billion last year, including $7.8 billion in the U.S.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
